epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
pharma · Atopic Dermatitis Eczema · Plaque Psoriasis · ARQT
Arcutis Biotherapeutics
Arcutis Biotherapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2945 Townsgate Rd, Westlake Village, California 91361, US HQ
2016 Founded
427 Employees
Public company Type
ARQT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2945 Townsgate Rd, Westlake Village, California 91361, US
- Founded
- 2016
- Employees
- 427
- Programs
- 27
- Drugs
- 3
- Patents
- 30
Arcutis Biotherapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Arcutis Biotherapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
nemolizumab
Dermatologicals (D11)Dermatologicals (D11) compound in Arcutis Biotherapeutics's portfolio. Molecular target: Interleukin-31 receptor subunit alpha.
- Target
- Interleukin-31 receptor subunit alpha
- Mechanism
- Interleukin-31 receptor subunit alpha inhibitor
-
roflumilast
Respiratory system (R03)US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor